Actavis antibiotic combo Avycaz OK'd for 2 infections

Actavis won the FDA's approval on 25 February to market Avycaz, an antibiotic combination containing ceftazidime and avibactam, to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

Actavis won the FDA's approval on 25 February to market Avycaz, an antibiotic combination containing ceftazidime and avibactam, to treat complicated intra-abdominal infections (cIAI) and complicated urinary tract infections (cUTI).

The drug is intended for use in adults who have limited or no alternative treatment options to treat those diseases.

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Anti-infective

More from Therapeutic Category